CCIA has released a White Paper on patent reform, available here.

It is particularly valuable as calling for broad reforms that look to institutional structures and incentives as opposed to fiddling at the edges.

One argument doesn't quite work for me, though. The claim is that since patents are working for some sectors (like pharma) and not for software, there is therefore a subsidy flowing from software to pharma. But we still don't know that on balance patents are doing more harm than good for software; assuming they are, the economic damage that is being done to software is just loss; is isn't being transferred to pharma somehow. Pharma would be doing fine with the current system even if it worked well for software.